ZVRA Zevra Therapeutics Inc
22,266
$4.73
$0.03
(0.63%)
| Watchers | 22,266 |
| 52-Wk Low | $3.89 |
| 52-Wk High | $7.28 |
| Market Cap | $197.97M |
| Volume | 143,551.00 |
| 52-Wk High | $7.28 |
| 52-Wk Low | $3.89 |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRAPR Newswire • 13 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
Share to Feed
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - HC Wainwright cut their FY2025 earnings per share estimates for shares of Zevra Therapeutics in a report issued on Wednesday, April 3rd. HC...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at Roth Capital cut their Q1 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note...
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zevra Therapeutics, Inc...
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zevra Therapeutics, Inc. ( Zevra or the Company ) (NASDAQ: ZVRA). The...
ATLANTA, April 02, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Zevra Therapeutics, Inc. ( Zevra or the Company ) (NASDAQ: ZVRA) complied with federal securities laws...